We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

REGULATORY INFORMATION MANAGEMENT SYSTEM (RIMS) MARKET ANALYSIS

Regulatory Information Management System (RIMS) Market Report, by Application (Registration, Submission, Publishing, e-Archiving, and Others), by Component (Software and Services), by Deployment (On-Premise and Cloud Based), by Enterprise Size (SMEs and Large Enterprises), by End Use (Pharmaceutical Industry, Biotechnology Industry, and Clinical Research Organizations), and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Size, Share, Trends, and Forecast 2019 - 2027

Regional Analysis

North America regulatory information management system (RIMS) market is expected to exhibit the highest CAGR over the forecast period

North America is anticipated to be dominant in the regulatory information management system (RIMS) market, due to high presence of pharmaceutical companies such as Amgen, GlaxoSmith, Novartis, Johnson & Johnson, and Gilead Sciences among others in countries such as the U.S. and Canada. Furthermore, according to a report by European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2016, North America accounted for 49.0% of world pharmaceutical sales compared to 21.5% of Europe. According to IMS Health data (MIDAS May 2017), 64.7% of sales of new medicines launched during the period 2011-2016 were in the U.S. market, compared to 17.5% in the European market. This depicts the potential of North American as well as European markets for adoption of regulatory information management software. North America is followed by Asia Pacific in terms of market share in the regulatory information management system (RIMS) market, owing to growing pharmaceuticals industry in countries such as China and India. This is evident with the fact that, according to International Trade Administration, rising per capita income, aging population, greater access to healthcare, and regulatory reform are key drivers that will enhance the appeal of China\'s pharmaceutical market.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.